Clinical Trial

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

Study acronym: PLATINUM
Completed Phase 2
View on ClinicalTrials.gov →
Summary
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-14; most recent amendment 2026-04-16.
Trial Details
NCT Number NCT07235033
Lead Sponsor Novartis Pharmaceuticals
Conditions Uncomplicated Plasmodium Falciparum Malaria
Enrollment 60 participants
Start Date 2024-01-23
Primary Completion 2025-03-05 (estimated)
Study Completion 2025-03-19 (estimated)
Updated on ClinicalTrials.gov 2026-05-07